biostudies-literatureUnknown15(2)Celik S<b>Background/Objectives</b>: Eltrombopag, a thrombopoietin receptor agonist, is widely used in the treatment of relapsed or refractory (R/R) immune thrombocytopenia (ITP). This study aimed to compare the efficacy, safety, and tolerability of generic eltrombopag (Rompag^®) with original eltrombopag (Revolade^®) in adult patients with R/R ITP. <b>Methods</b>: In this prospective, multicenter study conducted at 10 centers, 104 adult ITP patients were followed for at least 3 months. A total of 35 (33.7%) patients received Rompag^® and 69 (66.3%) received Revolade^®. The primary endpoint was platelet (PLT) response, defined as achieving a PLT count ≥50 × 10⁹/L and at least a twofold increase from baseline, without the need for rescue therapy oJournal of clinical medicine634https://www.ebi.ac.uk/biostudies/studies/S-EPMC12841940biostudies-literatureOriginal Versus Generic Eltrombopag in Patients with Immune Thrombocytopenia: A Prospective Multi-Center Experience on Efficacy and Safety.PMC12841940Selim CCelik SKırcalı ESenturk Yıkılmaz ADemircan VCiftciler RKurt Yuksel MKarabulut ZTYıldız APınar IEEroglu Kucukdiler AHAcar NGYaman SKeskin DAcar IHfalseOriginal Versus Generic Eltrombopag in Patients with Immune Thrombocytopenia: A Prospective Multi-Center Experience on Efficacy and Safety.<b>Background/Objectives</b>: Eltrombopag, a thrombopoietin receptor agonist, is widely used in the treatment of relapsed or refractory (R/R) immune thrombocytopenia (ITP). This study aimed to compare the efficacy, safety, and tolerability of generic eltrombopag (Rompag^®) with original eltrombopag (Revolade^®) in adult patients with R/R ITP. <b>Methods</b>: In this prospective, multicenter study conducted at 10 centers, 104 adult ITP patients were followed for at least 3 months. A total of 35 (33.7%) patients received Rompag^® and 69 (66.3%) received Revolade^®. The primary endpoint was platelet (PLT) response, defined as achieving a PLT count ≥50 × 10⁹/L and at least a twofold increase from baseline, without the need for rescue therapy o2026-01-01T00:00:00Z2026 Jan2026-06-15T03:18:51.898Z2026-06-15T03:08:51.149ZS-EPMC128419404159857310.3390/jcm15020634